Galenica Santé adds Merfen® and Vita-Merfen® to its OTC product portfolio
Wednesday, 22 February 2017
The Galenica Group is further strengthening its OTC product portfolio in the Galenica Santé Business unit. Its subsidiary Vifor Consumer Health is acquiring the two iconic Swiss brands Merfen® and Vita-Merfen® from GSK Consumer Healthcare Schweiz AG. Vifor Consumer Health is therefore entering a new market in the form of wound care and further expanding its position in the Swiss healthcare market.
Vifor Consumer Health is set to acquire the commercialisation rights for Merfen® and Vita-Merfen®, including the brands and approval in Switzerland, from GSK Consumer Healthcare. This will enable Vifor Consumer Health to establish a presence in the strong-selling Swiss wound disinfection and healing market, which is worth over CHF 50 million (street price – IMS Health 2016), and to further expand its position as a leading partner for pharmacies and drugstores in the Swiss healthcare market.
Other press releases
- Tuesday, 8 August 2017
- Wednesday, 7 June 2017